1. Late Relapses following High-Dose Autologous Stem Cell Transplantation (HD-ASCT) for Hodgkin’s Lymphoma (HL) in the ABVD Therapeutic Era 
Sarah F. Keller, Jennifer L. Kelly, Elizabeth Sensenig, Jennifer Andreozzi, Jamie Oliva, Lynn Rich, Louis Constine, Michael Becker, Gordon Phillips, Jane Liesveld, Richard I. Fisher, Steven H. Bernstein, Jonathan W. Friedberg 
Biology of Blood and Marrow Transplantation 
Volume 18, Issue 4, Pages (April 2012)
DOI: /j.bbmt
Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1 Summary of patient outcomes following HD-ASCT.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions

3. Figure 2
Kaplan-Meier estimates of (A) EFS (years; N = 95); and (B) OS (years; N = 95).
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions

4. Figure 3
Kaplan-Meier estimates of (A) OS from time of relapse, stratified by length of time between HD-ASCT and relapse (n = 51 relapses, n = 6 TRM excluded), log-rank P < .001; and (B) OS from time of relapse for those that relapsed 1 to 3 years post-HD-ASCT vs those that relapsed >3 years post-HD-ASCT (n = 26), log-rank P = .93, hazard ratio for OS with relapse >3 years post-HD-ASCT vs OS with relapse 1 to 3 years post-HD-ASCT = 1.05 (95% confidence interval, ).
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions